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Abstract
Background: Fractalkine (FKN) is involved in the occurrence and development of human lupus nephritis. It is
known to be upregulated by lipopolysaccharide (LPS) as a stimulus in vivo. MRL/lpr mice have been used as an in
vivo model to study lupus nephritis. Methylprednisolone (MP) is used widely in the clinical treatment of progressive
glomerular diseases such as lupus nephritis. The aim of this study is to explore the mechanism of LPS
induced FKN expression and to determine whether other molecular mechanisms contribute to the signaling
pathway of MP action in MRL/lpr mice.
Methods: Forty-eight female MRL/lpr mice at 12 weeks of age were randomly distributed into six groups.
Each group received various treatments for 8 weeks by receiving twice weekly intraperitoneal injections of (1)
MP (MP-treated mice), of (2) SC-514 (SC-514-induced mice), of (3) normal saline and a single injection of LPS
(LPS-induced mice), of (4) MP and a single injection of LPS (LPS + MP mice), of (5) SC-514 and a single
injection of LPS (LPS + SC mice) and of (6) normal saline (control mice). One-way ANOVA was used for data
analysis and P value <0.05 was considered statistically significantly.
Results: The expression of FKN and NF-kappaB p65 mRNA was detected by qPCR. The expression of FKN
protein and the activation of NF-kappaB p65 were detected by immunohistochemistry and western blots respectively.
The expression of FKN in the kidney of LPS induced mice was significantly increased and this was mediated by
increased expression of NF-κB p65 and an increase in NF-kappaB phospho-p65. MP reduced proteinuria and
ameliorated the renal damage in MRL/lpr mice. MP as well as the NF-kappaB inhibitor, SC-514, inhibited the
LPS-induced increase of expression of FKN and the activation of NF-kappaB.
Conclusions: The results indicate that MP attenuates LPS-induced FKN expression in kidney of MRL/lpr mice
through the NF-kappaB pathway.
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Background
Systemic lupus erythematosus (SLE) is a systemic auto-
immune disease. Renal involvement, namely lupus neph-
ritis, is a common and potentially lethal complication of
SLE. It involves the production of pathogenic autoanti-
bodies, hypocomplementemia, deposition of immune
complexes, inflammation and renal damage [1]. The
morphologic changes in lupus nephritis include a
spectrum of vascular, glomerular and tubulointerstitial
lesions. Glomerular injury comprises mesangial hyper-
cellularity and matrix accumulation as the mesangial
pattern, with leukocyte accumulation, endothelial cell in-
jury and endocapillary proliferation as the endothelial
pattern, and a nonexudative, nonproliferative capillary
wall lesion as the epithelial pattern [2]. Although the
pathogenesis of lupus nephritis has yet to be determined,
increasing lines of evidence have indicated a potential
role of cytokines in the development and progression of
lupus nephritis [3].
MRL/MpJ-lpr/lpr (MRL/lpr) mice develop spontan-
eous autoimmune diseases and the main histopatho-
logical features of the glomerular lesions resemble those
shown in human lupus nephritis. These serious glom-
erular diseases that develop spontaneously in MRL/lpr
mice are commonly associated with cytokine abnormal-
ities. FKN is a unique member of the CX3C superfamily
of chemokines [4] and acts as a chemotatic agent. It also
functions as an adhesion molecule and mediates im-
mune injury and is involved in the occurrence and de-
velopment of renal diseases [5–7], including lupus
nephritis [8]. FKN can be synthesized by a variety of
progressive glomerular diseases [9–11] in lupus-prone
MRL/lpr mice [8, 11, 12]. It is produced as an intracellu-
lar precursor protein and transported to the cell surface
as a mature protein after being N-glycosylated [13]. FKN
is significantly expressed in the glomeruli of 12-week-old
MRL/lpr mice [14]. N-terminal-truncated analogs acting
as FKN antagonists can reduce glomerular damage and
interstitial mononuclear cell infiltration [14]. FKN is
produced secondary to the deposition of immune com-
plexes [14]. These results indicate that FKN may be
able to modify the progression of renal damage in
MRL/lpr mice.
NF-κB also has been shown to be involved in lupus
nephritis [15]. LPS can induce moderate albuminuria
and aggravate glomerular nephritis in MRL/lpr mice
[16]. LPS induces expression of inflammatory cytokines
and activation of the NF-κB pathway [17], FKN mRNA
and protein expression and these have been shown to in-
crease in mesangial cells stimulated with LPS [18]. FKN
has also been shown to induce proliferation of mesangial
cells [19]. NF-κB may thus be an important target for an
anti-inflammatory approach to treat LPS-induced alter-
ations of FKN expression.
Current induction therapy for some severe forms of
lupus nephritis such as Class III/IV are various combina-
tions of glucocorticoids with other agents [20] because
of their important anti-inflammatory and immunosup-
pressive effects [21, 22]. In human lupus nephritis, the
expression of FKN in glomeruli correlates with the his-
topathologic activity index whereby the glomerular FKN
expression has a tendency to decrease with glucocortic-
oid therapy [8]. MP is one of the glucocorticoids used as
an initial starting point of treatment for lupus nephritis.
In respiratory epithelial cells, the NF-κB pathway regu-
lates the expression of FKN, and glucocorticoids have
been shown to inhibit FKN expression in a glucocortic-
oid receptor-dependent (RU486 sensitive) manner [23].
The mechanisms by which MP inhibits inflammation
and the signaling pathways in lupus nephritis, such as
the FKN and NF-κB pathways, are not fully understood.
This study uses a molecular biology-based approach to
demonstrate the expression of FKN and activation of
NF-κB in MRL/lpr mice treated with LPS. In addition,
the molecular mechanisms and the pathways involved in
LPS-induced FKN expression in lupus nephritis and the
molecular mechanisms by which MP modulates lupus
nephritis are explored.
Methods
Animals
MRL/lpr mice weighing 18-21 g were purchased from the
Model Animal Research Center of Nanjing University
(Nanjing, China). Mice were fed under conditions free of
specific pathogens at 22-25 °C and kept in an environment
of 40-60 % relative humidity in the Animal Research
Institute of Youjiang Medical University for Nationalities.
All procedures involving mice were approved by the
Committee on the Ethics of Animal Experiments of
Youjiang Medical University for Nationalities and were
carried out in accordance with the National Institute of
Health guidelines.
Experimental protocol
Forty-eight female MRL/lpr mice at 12 weeks of age
were randomly distributed into six groups that received
intraperitoneal injections as follows:
(1)twice weekly injections for 8 weeks of MP (25 mg/kg
body weight, Pfizer, Belgium) - MP-treated mice
(2)twice weekly injections for 8 weeks of SC-514 (25 mg/
kg body weight, SML0557 from Sigma-Aldrich, USA).
SC-514 is a cell-permeable, potent and selective
ATP competitive inhibitor of NF-κB kinase-2 that
specifically blocks NF-κB-dependent gene expression.
- SC514-treated mice
(3)twice weekly injections for 8 weeks of normal saline
and a single injection of LPS (5.0 mg/kg body
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weight, L2880, Sigma-Aldrich, USA) 8 h prior to
sacrifice as described previously [24] - LPS-induced
mice
(4)twice weekly injections for 8 weeks of MP and a
single injection of LPS 8 h prior to sacrifice - LPS +
MP mice
(5)twice weekly injections for 8 weeks of SC-514 and a
single injection of LPS 8 h prior to sacrifice - LPS +
SC mice
(6)twice weekly injections for 8 weeks of normal saline
- control mice.
Assessment of urine protein and renal function
Urine samples were collected using metabolic cages for
24 h before sacrifice. Urine protein was measured as
described previously [25]. Blood serum levels of urea
nitrogen (BUN) and creatinine (Cr) were determined at
20 weeks when all mice were subsequently sacrificed
8 h after the last injection of LPS or saline as described
previously [25]. Renal cortical samples were harvested
at this time.
Histopathological analysis
Tissue samples were fixed with 10 % formalin in
0.01 mol/L phosphate buffer (pH 7.2) and then embed-
ded in paraffin for histopathology. The slides were
stained with periodic acid-silver methenamine (PASM)
for examination under a light microscope. The examin-
ation of renal pathology was performed in a blinded
fashion by a pathologist.
RNA isolation and real-time PCR assays
Total RNA of renal cortices was extracted using TRIzol
reagent (Invitrogen, USA) according to the manufac-
turer’s instructions. First-strand cDNA was then made
from the total RNA using M-MLV reverse transcriptase
(C28025, Invitrogen, Shanghai, China) with random
primers. The expression levels of FKN and p65 were
measured by real-time qPCR using SYBR Green I
(204143, Qiagen, Germany) through forced denaturation
at 95 °C for 30 s and 40 cycles of denaturation at 95 °C
for 10 s, annealing and extension at 60 °C for 30 s each.
Primer sequences were designed using the Primer Prem-
ier 3.0 program. The optimal reference genes were
EEF1A1 and GAPDH in MRL/lpr mice, determined by
geNorm 3.5 software as described previously [26]. Pri-
mer sequences (Invitrogen, USA) were as follows: mice
FKN forward 5′- CGACAAGATGACCTCACGAA -3′,
reverse 5′- CTGTGTCGTCTCCAGGACAA -3′(NM_0
09142.3); mice P65 forward 5′- TAAGCCGTACAC
AGCCACTG -3′, reverse 5′ - CCAGGTAAATGGC
TGCAGAT -3′ (NM_010908.4); mice EEF1A1 forward
5′- TAGACGAGGCAATGTTGCTG -3′, reverse 5′ - A
GCGTAGCCAGCACTGATTT -3′(NM_010106.2); mice
GAPDH forward 5′- AACTTTGGCATTGTGGAAGG -3′,
reverse 5′ - GGATGCAGGGATGATGTTCT -3′(NM_00
8084.2). The comparative gene expression was calcu-
lated by 2-△△Ct method as described previously [27].
Immunohistochemistry
For immunohistochemistry (IHC), formalin-fixed and
paraffin embedded renal sections were prepared as
described previously, and then incubated in 3 %
hydrogen peroxide for 15 min and normal goat serum
for 10 min to block endogenous peroxidase. The sec-
tions were incubated with either anti-FKN antibody
(ab25088, Abcam Ltd, Hong Kong, 1:200 dilution) or
anti-NFκB p65 antibody (ab31481, Abcam Ltd, Hong
Kong, 1:100 dilution) overnight at 4 °C and then in-
cubated with goat polyclonal secondary antibody to
rabbit IgG-H&L (HRP) (ab6721, Abcam Ltd, Hong
Kong, 1:500 dilution) for 30 min at 37 °C. Normal
rabbit serum served as a negative control. To com-
pare the expression levels of FKN and p65 in glom-
erular cells by IHC, staining intensity was evaluated
semiquantitatively according to the previous paper
[10]. Forty or more glomeruli were examined on each
slide and assigned values of staining intensity from 0
to 3+. An intensity score was calculated as: (% glom-
eruli intensity (negative) × 0) + (% glomeruli intensity (trace
intensity) × 0.5) + (% glomeruli (1+) intensity × 1) + (%
glomeruli (2+) intensity × 2) + (% glomeruli (3+) inten-
sity × 3). The values typically ranged from 0 to a max-
imum of 300.
Western blot analysis
Aliquots of total kidney homogenate from individual an-
imals were diluted in lysis buffer (50 mM Tris–HCl,
pH 7.4, 150 mM NaCl, 1 % Triton X-100, 0.1 % SDS,
2 mM EDTA, 0.1 mM EGTA, 5 mM NaF, 1 mM
Na3VO4, 5 mM Na2PO4 and 1 × proteinase inhibitor
cocktail (Beyotime Institute of Biotechnology, China) to
a final protein concentration of 2 μg/μL. Western blot
analysis was conducted and quantified as described by
Müller et al. [28]. The following antibodies were used:
rabbit anti-FKN antibody (ab25088, Abcam Ltd, Hong
Kong, 1:100 dilution) or anti-NFκB p65 antibody
(ab31481, Abcam Ltd, Hong Kong, 1:200 dilution) or
anti-NF-κB phospho p65 antibody (ab28810, Abcam Ltd,
Hong Kong, 1:100 dilution) to evaluate the activity of
NF-κB pathway, and mouse anti-beta actin monoclonal
antibody (AA128, Beyotime Institute of Biotechnology,
China, 1:500 dilution) followed by the goat polyclonal
secondary antibody to rabbit IgG-H&L (HRP) (ab6721,
Abcam Ltd, Hong Kong, 1:1000 dilution) or anti-mouse
IgG-H + L (A0216, Beyotime Institute of Biotechnology,
China, 1:1000 dilution). The image of western blots was
scanned by Quantity One software and the original
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intensity of each specific band was quantified with freeware
image analysis software, NIH Image (National Institute of
Health, Bethesda, Md., USA).
Statistical analysis
Data are reported as means ± SE for normally distrib-
uted data and median (range) for nonparametric
data. The comparisons of gene expression levels be-
tween groups were performed by using the one-way
ANOVA for parametric data, F-test for equality of
variances and Newman-Keuls test for heterogeneity
of variance. All analyses were conducted with SPSS
software, version18.0. P value < 0.05 was considered
statistically significantly.
Results
MP reduces proteinuria and renal function defects in
MRL/lpr mice
MRL/lpr mice showed moderate proteinuria and renal
function defects at 20 weeks. Proteinuria in 20-week-old
MRL/lpr mice was 92.5 ± 26.3 mg/24 h. An intraperi-
toneal injection of LPS did not induce proteinuria
(96.8 ± 32.6 mg/24 h) but MP was able to reduce this
level significantly (48.3 ± 22.8 mg/24 h; P < 0.05).
Compared with LPS-induced MRL/lpr mice, protein-
uria in LPS +MP-treated MRL/lpr mice was decreased
(56.2 ± 23.6 mg/24 h; P < 0.01; Fig. 1a). There was no
significant difference of proteinuria between SC-514-
treated MRL/lpr mice and control mice, and between
LPS + SC-treated MRL/lpr mice and LPS-induced
mice. The LPS-induced MRL/lpr mice showed signifi-
cantly increased serum levels of BUN and Cr, and
there was a dramatic improvement in renal function
in the MP-treated MRL/lpr mice. There was no sig-
nificant difference of serum BUN and Cr between
SC-514-treated MRL/lpr mice and control mice, and
between LPS + SC-treated MRL/lpr mice and LPS-
induced mice (Fig. 1b and c).
MP ameliorates the severe renal lesions in MRL/lpr mice
At the age of 20 weeks, the renal cortex of MRL/lpr
mice showed widening of the mesangial region, in-
creased mesangial matrix, proliferation of mesangial cells
(the degree of proliferation was between 25 and 50 %),
lobulation of the glomerulus and formation of partial
cellular crescents. These changes are indicative of renal
structural damaged. The renal cortex of SC-514-treated
MRL/lpr mice also showed a similar extent of mesangial
cell proliferation and fusion of podocytes, but no forma-
tion of partial cellular crescents and less electron-dense
deposits in the mesangial region. The renal cortex of LPS-
induced and LPS + SC-treated MRL/lpr mice showed
mesangial cell proliferation (proliferation degree of more
than 50 %), with endothelial cell proliferation, vascular
loop compression, partial occlusion, interstitial inflam-
mation and infiltration of lymphocytes, monocytes and
eosinophils. However, the renal cortex of MP and LPS +
MP-treated mice showed a reduction in mesangial
matrix, lowered mesangial cell proliferation (with a pro-
liferation degree of between 25 and 50 %) and no cres-
cent formation and interstitial inflammation (Fig. 2).
MP and SC-514 inhibit gene expression of FKN and NF-κB
in MRL/lpr mice
The semiquantification analysis of FKN and NF-κB p65
mRNA in renal cortex was compared between the
groups of mice by real-time PCR. The relative FKN and
p65 mRNA levels (normalized to EEF1A1 and GAPDH
mRNA) in renal cortex of LPS-induced mice were sig-
nificantly greater than those in control mice. The FKN
and p65 mRNA levels of MP and SC-514 mice were
down-regulated compared with control mice. The FKN
Fig. 1 Proteinuria and renal function in MRL/lpr mice. a Urine protein levels in MRL/lpr mice. *P < 0.05 when compared with control mice;
## P < 0.01 when compared with LPS mice. b Serum levels of BUN in MRL/lpr mice. *P < 0.05 when compared with control mice; *P < 0.05 when
compared with control mice; ## P < 0.01 when compared with LPS mice. c Serum levels of Cr in MRL/lpr mice. **P < 0.01 when compared with
control mice; *P < 0.05 when compared with control mice; # P < 0.05 when compared with LPS mice
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and p65 mRNA levels of LPS +MP-treated and LPS +
SC-treated mice were down-regulated compared with
LPS-induced mice (Fig. 3).
Localization and the expression of renal FKN and p65
Protein in MRL/lpr mice
In kidney sections of MRL/lpr mice stained by IHC, the
expression of FKN and p65 protein was seen mainly in
the cytoplasm of podocytes, endothelial cells in glomeru-
lar and some renal tubular epithelial cells (Figs. 4 and 5).
The expression of FKN and p65 protein was compared
between the different groups of mice. According to
semiquantitative evaluation, the intensity scores of FKN
were 142.5 ± 38.7, 196.7 ± 36.5, 96.3 ± 21.6, 99.3 ± 21.5,
102.8 ± 32.4 and 118.7 ± 29.5 in control, LPS-induced,
MP-treated SC-514-treated, LPS +MP and LPS + SC
mice respectively. The intensity scores of p65 were
98.2 ± 32.5, 143.8 ± 44.2, 62.3 ± 18.5, 58.5 ± 17.7, 75.2 ±
21.3 and 74.5 ± 22.6 in control, LPS-induced, MP-
treated SC-514-treated, LPS +MP and LPS + SC mice
respectively. There was increased expression of glomerular
FKN and p65 protein in LPS-induced mice (P < 0.01 and
P < 0.05 respectively) when compared to control mice, a
decreased expression in MP-treated mice compared to
control mice (P < 0.05) and a decreased expression in
LPS +MP and LPS + SC mice compared to LPS-
induced mice (P < 0.01 and P < 0.05 respectively).
MP as well as SC-514 inhibit FKN renal protein expression
and NF-κB activation in MRL/lpr mice
Western blot analysis showed the expression of FKN
and activation of NF-κB by testing for phospho p65 in
renal cortex of MRL/lpr mice. As shown in Fig. 6, LPS
stimulated the expression of FKN and phospho p65
Fig. 2 Renal histopathological staining of MRL/lpr mice by PASM. a Control mice show widening of the mesangial region, increased mesangial
matrix, a mesangial cells proliferation degree of between 25-50 % and formation of cellular crescent. b LPS-induced mice show mesangial cells
proliferation degree of more than 50 %, and inflammation. c MP-treated mice show mild mesangial matrix and mesangial cells proliferation.
d SC-514-treated mice show increased mesangial matrix, a mesangial cells proliferation degree of between 25-50 %. e LPS + MP-treated mice
show mild mesangial matrix and mesangial cells proliferation. f LPS + SC-treated mice show mesangial cells proliferation degree of more than
50 % (original magnification, ×400)
Fig. 3 Expression of FKN and NF-κB p65 mRNA in renal cortex. The semiquantification analysis of (a) FKN and (b) p65 mRNA by qPCR. **P < 0.01
when compared with the control mice; *P < 0.05 when compared with the control mice; ## P < 0.01 when compared with LPS-induced mice
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protein with MP or SC-514 suppressing LPS-induced ex-
pression of FKN and phospho p65 protein in MRL/lpr
mice kidney. These results are consistent with the data
relating to FKN and p65 mRNA expression and the
immunohistological findings.
Discussion
The results demonstrate that LPS induced the expres-
sion of FKN and activation of NF-κB in renal cortex of
MRL/lpr mice and that MP significantly reduced pro-
teinuria, ameliorated renal function, severity of renal
pathology and LPS-induced kidney injury in MRL/lpr
mice. MP downregulated the LPS-induced FKN expres-
sion and NF-κB activation in kidney of MRL/lpr mice,
consistent with the role of the NF-κB inhibitor, SC-514.
Chemokines are known to be involved in the lupus dis-
ease process. CCL2 (also known as monocyte chemotactic
protein-1, MCP-1) [29] and CXCL10 are good biomarkers
to indicate the activity of lupus nephritis [30] and the po-
tential flares in SLE [31]. CCL2 and CXCL10 are known
to be raised in the blood of SLE patients [32]. Compared
to treated patients, expression of CCL2 and CXCL10
mRNA in untreated SLE patients’ blood were significantly
higher. This indicates that chemokines are potential thera-
peutic targets in SLE patients [33]. Kulkarni et al. [34]
used the mNOX-E36 to inhibit CCL2 in MRL/lpr mice
and found prolonged survival associated with the im-
provement of lupus nephritis. In addition, CCL2 antago-
nists have been shown to be beneficial in the treatment of
lupus nephritis. Kassianos et al. demonstrated recently the
role of FKN and its receptor CX3CR1 in the recruitment
and retention of human kidney dendritic cells (DCs), and
showed the TGF-β-producing, CX3CL1-expressing CD1c+
DCs were recruited and retained within the tubuleintersti-
tium during fibrotic kidney disease via proximal tubular
epithelial cell (PTEC)-derived FKN [35].
Fig. 4 Immunohistochemistry for FKN within glomerular lesions in MRL/lpr mice. a Control mice, b LPS-induced mice, c MP-treated mice,
d SC-514-treated mice, e LPS + MP-treated mice, f LPS + SC-treated mice (original magnification, ×400)
Fig. 5 Immunohistochemistry for p65 within glomerular lesions in MRL/lpr mice. a Control mice, b LPS-induced mice, c MP-treated mice,
d SC-514-treated mice, e LPS +MP-treated mice, f LPS + SC-treated mice (original magnification, ×400)
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Expression of FKN mRNA and protein significantly in-
creased in the renal cortex of the LPS-induced group in
lupus mice, which shows that LPS can induce FKN ex-
pression in MRL/lpr mice. These data are consistent
with the results seen in mesangial cells in vitro [18]. MP
inhibited significantly the expression of FKN mRNA
and protein in renal cortex of MRL/lpr mice. These ef-
fects correlated with a reduction in proteinuria as well
as amelioration of renal function and renal pathology.
SC-514 is a selective and reversible inhibitor of IKKβ
(IKK-2), affecting NF-κB nuclear import/export as well
as the phosphorylation and transactivation of p65. SC-
514 was used to suppress the NF-κB activity in this
study. SC-514 also significantly inhibited expression of
FKN mRNA and protein in renal cortex of MRL/lpr
mice. The results suggest that MP as well as SC-514
can inhibit the increased expression of FKN induced by
LPS in MRL/lpr mice. However, the effect of SC-514
was not paralleled to that of MP on proteinuria, renal
function and glomerular proliferation in MRL/lpr mice.
Therefore, in addition to NF-κB pathway, there may be
some other mechanisms involved in the treatment of
lupus nephritis that needs to be explored.
IκBs, which regulate the nuclear translocation of NF-
κB, are critically associated to the differentiation of B
cells and with the auto-antibodies produced during pro-
gression of SLE disease [36]. Activation of NF-κB in
renal cortex in MRL/lpr mice was detected in this study.
The significant increase in expression of NF-κB p65 and
activation of NF-κB induced by LPS probably contribute
to the progression of glomerular lesions in the lupus
nephritis model. MP treatment significantly inhibited ex-
pression of NF-κB p65 and activation of the NF-κB path-
way, which was confirmed by the use of the NF-κB
inhibitor, SC-514. These effects are likely to be associ-
ated with expression of FKN mRNA and protein. The
other chemokine member, CXCL12 and its receptor
CXCR4, have been shown to be markedly elevated in in-
fected lupus mice via activation of the NF-κB signaling
pathway [37]. The data presented here are consistent
with previous observations summarizing the cytokine-
suppressing effects of NF-κB inhibitors resulting in a re-
duced FKN expression during inflammation-associated
diseases [38]. Accordingly, these results are consistent
for a central mechanism of MP in modulation of FKN
expression by suppressing the activation of NF-κB dur-
ing lupus nephritis.
Conclusions
This study confirms early findings that LPS-induced ex-
pression of FKN in the kidney of MRL/lpr mice is medi-
ated through the NF-κB pathway with the attenuation of
LPS-induced FKN expression by MP being accompanied
by the suppression of NF-κB activation. This leads us to
conclude that the mechanism of action of MP may be
partly specific to the FKN gene and that it mediates its
suppressive effects through the NF-κB-dependent path-
way in lupus nephritis. With respect to whether FKN con-
tributes to the disease progression, more studies are
required on the FKN-CX3CR1 system in order to explore
therapeutic potential in lupus nephritis.
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